// App-Quantinova.ai

: Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.

Researchers

Presenter

  • Samuel Tremblay

Principal Investigators

  • Mofarej Alhogbani

  • Andrew Weickhardt

  • Ian D. Davis

  • Andrew Mark Scott

  • Rodney J. Hicks

  • Ur Metser

  • Sue Chua

  • Reena Davda

  • Shonit Punwani

  • Heather Ann Payne

  • Nina Tunariu

  • Bao Ho

  • Sympascho Young

  • Glenn Bauman

  • Louise Emmett

  • Frederic Pouliot

Medical Centers

  • Laval University and CHUQ, Quebec City, QC, Canada

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Monash University Eastern Health Clinical School, Box Hill, VIC, Australia

  • Department of Oncology, University College London and University College London Hospital, London, United Kingdom

  • Department of Oncology, University of Western Ontario, London, Ontario, London, ON, Canada

  • St Vincents Hospital, Sydney, Australia

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Department of Molecular Imaging and Therapy, Austin Health and University of Melbourne

  • Kings College London, London, United Kingdom

  • Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • London Health Sciences Center, London, ON, Canada

  • NCRI, London, United Kingdom

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Faculty of Medicine, UNSW, Sydney, Australia

  • Olivia Newton-John Cancer Research Institute and La Trobe University, Heidelberg, Australia

Locations

  • United Kingdom

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Breakpoint Cluster Region

  • Choline

  • Folate Hydrolase 1

Drug/Treatment

  • Choline bitartrate

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved